Floatz logo

Anti-Cd19/20-Car Vector-Transduced T Cells

B Cell Lymphoma

University Hospital, Basel, SwitzerlandCell therapyPhase 1/2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Zanubrutinib
The First Affiliated Hospital of Soochow University
Phase 4BBB
Chimeric Antigen Receptor Modified T Cells Infusion
The First Affiliated Hospital of Soochow University
Phase 2/3BB
VINCRISTINE SULFATE
The First Affiliated Hospital of Soochow University
Phase 4BB
Cart-19 And 20 Cells
Henan Cancer Hospital
Phase 2BB
Cart-19 Cells
Shenzhen BinDeBio Ltd.
Phase 2/3BB

View all 50 →

Same molecule, other indications

Anti-Cd19/20-Car Vector-Transduced T Cells is also rated in:

Hematopoietic/Lymphoid CancerDormant
CCC
Indicative ·
52 / 100
View asset →
Adult Acute Lymphoblastic Leukemia in RemissionDormant
CCC
Indicative ·
50 / 100
View asset →
B-cell Adult Acute Lymphoblastic LeukemiaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →